Skip to main content

Human Genome Sciences Appoints Richard Holbrooke, Richard Danzig to Board of Directors

NEW YORK, May 24 - Human Genome Sciences said Thursday it has appointed Richard Holbrooke, former US ambassador to the United Nations, and Richard Danzig, former secretary of the Navy, to positions on its board of directors.

Holbrooke will replace Beverly Sills Greenough, who is resigning from the board for personal reasons, according to a statement. With the addition of Danzig, the company now has ten directors.

In addition to serving as ambassador to the United Nations and in other high level government positions, Holbrooke has also served as managing editor of Foreign Policy magazine and held senior positions at Wall Street firms Credit Suisse First Boston and Lehman Brothers. Holbrooke currently serves on the boards of AIG and the National Endowment of Democracy and holds the positions of vice chairman at Perseus, a merchant bank and private equity fund management company.

Danzig has served as Secretary of the Navy, as an adjunct professor at Syracuse University, and as a partner in the law firm Latham and Watkins. As an attorney, Danzig practiced white-collar crime defense work, civil litigation and corporate law. Danzig is also on the board of National Semiconductor.

"We are honored to have Richard Holbrooke and Richard Danzig join our board of directors," said Willaim Haseltine, CEO of Human Genome Sciences. "Their experiences at the top levels of government and finance will serve us well as we continue to discover and develop novel drugs and strive towards our goal of becoming a biopharmaceutical company that also manufactures and markets its own products."  
The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.